The Alzheimer's Association and the U.S. POINTER study's Coordinating Center at Wake Forest University Medical Center have been closely monitoring the novel coronavirus (COVID-19) and are acting to ensure the safety of participants and staff, and to protect the scientific integrity of the study to the best of our ability.
Based on guidance from the Centers for Disease Control (CDC) and local and regional authorities, U.S. POINTER study leadership is permitting our study locations to end the "Pause" and to officially restart the study on July 13th.
Please know that we will continue to monitor the COVID-19 situation across all of our study locations and we will take recommended precautions to protect the health and safety of U.S. POINTER participants and staff as we restart.
For current participants: Your U.S. POINTER site staff will contact you by telephone to schedule visits and/or Team Meetings. We look forward to seeing you and continuing what we started in this important study. We are committed to working with you so that together, we can find a way to prevent memory loss in older adults!
For individuals interested in participating in U.S. POINTER: Click here for site contact information to see if you might be eligible to participate in the study.
For individuals interested in learning more about U.S. POINTER: Click here for more information.
The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is a two-year clinical trial to evaluate whether lifestyle interventions that simultaneously target multiple risk factors protect cognitive function in older adults (age 60-79) at increased risk for cognitive decline. The currently participating sites are University of California - Davis, Rush University Medical Center, and Wake Forest School of Medicine.